CytomX Therapeutics, Inc. Operating Expenses
CytomX Therapeutics, Inc. (CTMX) reported Operating Expenses of $25.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- CytomX Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $25.20M, a 26.35% increase year-over-year.
- CytomX Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $29.93M, a 5.77% increase year-over-year.
- CytomX Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $28.59M, a 40.08% increase year-over-year.
- CytomX Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $21.73M, a 25.89% decline year-over-year.
- CytomX Therapeutics, Inc. operating expenses for fiscal 2025 was $98.56M, a 12.86% decline from fiscal 2024.
- CytomX Therapeutics, Inc. operating expenses for fiscal 2024 was $113.11M, a 5.02% increase from fiscal 2023.
- CytomX Therapeutics, Inc. operating expenses for fiscal 2023 was $107.70M, a 30.29% decline from fiscal 2022.
- CytomX Therapeutics, Inc. operating expenses for fiscal 2022 was $154.50M, a 0.75% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $25.20M 10-Q · filed 2026-08-06 | $55.13M 10-Q · filed 2026-08-06 | $83.72M derived: sum of 3 quarters · filed 2026-08-06 | $105.45M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $29.93M 10-Q · filed 2026-05-07 | $58.52M derived: sum of 2 quarters · filed 2026-05-07 | $80.26M derived: sum of 3 quarters · filed 2026-05-07 | $100.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $28.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $50.33M derived: sum of 2 quarters · filed 2026-03-16 | $70.27M derived: sum of 3 quarters · filed 2026-08-06 | $98.56M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $21.73M 10-Q · filed 2025-11-06 | $41.67M derived: sum of 2 quarters · filed 2026-08-06 | $69.97M 10-Q · filed 2025-11-06 | $90.39M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $19.94M 10-Q · filed 2026-08-06 | $48.24M 10-Q · filed 2026-08-06 | $68.65M derived: sum of 3 quarters · filed 2026-08-06 | $97.97M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $28.30M 10-Q · filed 2026-05-07 | $48.71M derived: sum of 2 quarters · filed 2026-05-07 | $78.03M derived: sum of 3 quarters · filed 2026-05-07 | $111.60M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $49.73M derived: sum of 2 quarters · filed 2026-03-16 | $83.30M derived: sum of 3 quarters · filed 2026-03-16 | $113.11M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $29.32M 10-Q · filed 2025-11-06 | $62.89M derived: sum of 2 quarters · filed 2025-11-06 | $92.69M 10-Q · filed 2025-11-06 | $119.91M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $33.57M 10-Q · filed 2025-08-07 | $63.37M 10-Q · filed 2025-08-07 | $90.59M derived: sum of 3 quarters · filed 2025-08-07 | $113.85M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $29.81M 10-Q · filed 2025-05-12 | $57.02M derived: sum of 2 quarters · filed 2025-05-12 | $80.28M derived: sum of 3 quarters · filed 2025-05-12 | $108.35M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $27.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $50.47M derived: sum of 2 quarters · filed 2025-03-06 | $78.55M derived: sum of 3 quarters · filed 2025-03-06 | $107.70M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $23.26M 10-Q · filed 2024-11-07 | $51.33M derived: sum of 2 quarters · filed 2024-11-07 | $80.48M 10-Q · filed 2024-11-07 | $110.12M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $28.07M 10-Q · filed 2024-08-08 | $57.22M 10-Q · filed 2024-08-08 | $86.86M derived: sum of 3 quarters · filed 2024-08-08 | $127.71M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $29.15M 10-Q · filed 2024-05-08 | $58.78M derived: sum of 2 quarters · filed 2024-05-08 | $99.64M derived: sum of 3 quarters · filed 2024-05-08 | $142.55M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $29.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $70.49M derived: sum of 2 quarters · filed 2024-03-11 | $113.39M derived: sum of 3 quarters · filed 2024-03-11 | $154.50M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $40.86M 10-Q · filed 2023-11-07 | $83.76M derived: sum of 2 quarters · filed 2023-11-07 | $124.87M 10-Q · filed 2023-11-07 | $170.90M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $42.91M 10-Q · filed 2023-08-08 | $84.01M 10-Q · filed 2023-08-08 | $84.01M 10-Q · filed 2022-08-04 | $130.04M derived: sum of 3 quarters · filed 2023-08-08 | $170.27M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $41.10M 10-Q · filed 2023-05-09 | $87.14M derived: sum of 2 quarters · filed 2023-05-09 | $127.36M derived: sum of 3 quarters · filed 2023-05-09 | $162.86M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $46.03M 10-K/A · filed 2023-03-27 | $86.26M derived: sum of 2 quarters · filed 2023-03-27 | $121.76M derived: sum of 3 quarters · filed 2023-03-27 | $153.35M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $40.23M 10-K/A · filed 2023-03-27 | $75.72M derived: sum of 2 quarters · filed 2023-03-27 | $107.32M 10-K/A · filed 2023-03-27 | $138.47M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-06-30 | $35.49M 10-K/A · filed 2023-03-27 | $67.09M 10-K/A · filed 2023-03-27 | $98.24M derived: sum of 3 quarters · filed 2023-03-27 | $130.93M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-03-31 | $31.60M 10-K/A · filed 2023-03-27 | $62.75M derived: sum of 2 quarters · filed 2023-03-27 | $95.43M derived: sum of 3 quarters · filed 2023-03-27 | $128.18M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-12-31 | $31.15M 10-K/A · filed 2023-03-27 | $63.84M derived: sum of 2 quarters · filed 2023-03-27 | $96.58M derived: sum of 3 quarters · filed 2023-03-27 | $148.97M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | $32.68M 10-K/A · filed 2023-03-27 | $65.43M derived: sum of 2 quarters · filed 2023-03-27 | $117.81M 10-K/A · filed 2023-03-27 | $163.47M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-06-30 | $32.75M 10-K/A · filed 2023-03-27 | $85.13M 10-K/A · filed 2023-03-27 | $130.79M derived: sum of 3 quarters · filed 2023-03-27 | $167.22M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2020-03-31 | $52.39M 10-K/A · filed 2023-03-27 | $98.04M derived: sum of 2 quarters · filed 2023-03-27 | $134.47M derived: sum of 3 quarters · filed 2023-03-27 | $174.72M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2019-12-31 | $45.66M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $82.09M derived: sum of 2 quarters · filed 2023-03-27 | $122.33M derived: sum of 3 quarters · filed 2023-03-27 | $168.38M 10-K/A · filed 2023-03-27 | |
| 2019-09-30 | $36.43M 10-Q · filed 2020-11-05 | $76.68M derived: sum of 2 quarters · filed 2020-11-05 | $122.73M 10-Q · filed 2020-11-05 | $160.01M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $40.25M 10-Q · filed 2020-08-06 | $86.30M 10-Q · filed 2020-08-06 | $123.58M derived: sum of 3 quarters · filed 2021-02-24 | $159.26M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | $46.05M 10-Q · filed 2020-05-07 | $83.33M derived: sum of 2 quarters · filed 2021-02-24 | $119.02M derived: sum of 3 quarters · filed 2021-02-24 | $153.61M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $37.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $72.97M derived: sum of 2 quarters · filed 2021-02-24 | $107.56M derived: sum of 3 quarters · filed 2021-02-24 | $137.38M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $35.69M 10-Q · filed 2019-11-07 | $70.28M derived: sum of 2 quarters · filed 2019-11-07 | $100.09M 10-Q · filed 2019-11-07 | $128.41M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $34.59M 10-Q · filed 2019-08-07 | $64.41M 10-Q · filed 2019-08-07 | $92.73M derived: sum of 3 quarters · filed 2020-02-27 | $127.90M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $29.81M 10-Q · filed 2019-05-09 | $58.13M derived: sum of 2 quarters · filed 2020-02-27 | $93.30M derived: sum of 3 quarters · filed 2020-02-27 | $127.43M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $63.49M derived: sum of 2 quarters · filed 2020-02-27 | $97.61M derived: sum of 3 quarters · filed 2020-02-27 | $117.88M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $35.17M 10-Q · filed 2018-11-06 | $69.29M derived: sum of 2 quarters · filed 2018-11-06 | $89.56M 10-Q · filed 2018-11-06 | $110.06M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $34.13M 10-Q · filed 2018-08-08 | $54.39M 10-Q · filed 2018-08-08 | $74.89M derived: sum of 3 quarters · filed 2019-02-27 | $93.26M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $20.27M 10-Q · filed 2018-05-09 | $40.77M derived: sum of 2 quarters · filed 2019-02-27 | $59.14M derived: sum of 3 quarters · filed 2019-02-27 | $76.49M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $20.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $38.87M derived: sum of 2 quarters · filed 2019-02-27 | $56.22M derived: sum of 3 quarters · filed 2019-02-27 | $74.63M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $18.37M 10-Q · filed 2017-11-07 | $35.72M derived: sum of 2 quarters · filed 2017-11-07 | $54.13M 10-Q · filed 2017-11-07 | $67.64M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-06-30 | $17.35M 10-Q · filed 2017-08-07 | $35.76M 10-Q · filed 2017-08-07 | $49.27M derived: sum of 3 quarters · filed 2018-03-07 | $62.48M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-03-31 | $18.41M 10-Q · filed 2017-05-05 | $31.92M derived: sum of 2 quarters · filed 2018-03-07 | $45.13M derived: sum of 3 quarters · filed 2018-03-07 | $52.71M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2015-12-31 | $13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $26.72M derived: sum of 2 quarters · filed 2018-03-07 | $34.30M derived: sum of 3 quarters · filed 2018-03-07 | $40.91M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $13.21M 10-Q · filed 2016-11-03 | $20.79M derived: sum of 2 quarters · filed 2016-11-03 | $27.40M 10-Q · filed 2016-11-03 | $33.92M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2015-06-30 | $7.58M 10-Q · filed 2016-08-03 | $14.20M 10-Q · filed 2016-08-03 | $20.71M derived: sum of 3 quarters · filed 2017-03-02 | $26.09M derived: sum of 4 quarters · filed 2017-03-02 | |
| 2015-03-31 | $6.61M 10-Q · filed 2016-05-06 | $13.13M derived: sum of 2 quarters · filed 2017-03-02 | $18.51M derived: sum of 3 quarters · filed 2017-03-02 | ||
| 2014-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $11.90M derived: sum of 2 quarters · filed 2017-03-02 | $34.84M 10-K · filed 2017-03-02 | ||
| 2014-09-30 | $5.38M 10-Q · filed 2015-11-23 | $28.32M 10-Q · filed 2015-11-23 | |||
| 2013-12-31 | $15.84M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |